

GLAXOSMITHKLINE PLC

Form 6-K

October 17, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 17 October 2018

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No ☒

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms E Walmsley
  - b) Position/status Chief Executive Officer
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 

Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

a) Description of the financial instrument

b) Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

| Price(s) | Volume(s) |
|----------|-----------|
| £14.516  | 208       |

|         |     |
|---------|-----|
| £14.516 | 226 |
|---------|-----|

c) Price(s) and volume(s)

|         |     |
|---------|-----|
| £14.516 | 792 |
|---------|-----|

|         |     |
|---------|-----|
| £14.516 | 207 |
|---------|-----|

|         |     |
|---------|-----|
| £14.516 | 226 |
|---------|-----|

d) Aggregated information  
Aggregated volume Price

£14.516

- e) Date of the transaction 2018-10-12  
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')  
 a) Name Mr R G Connor  
 b) Position/status President, Global Vaccines  
 c) Initial notification/ amendment Initial notification  
 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  
 a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793  
 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted  
 Ordinary shares of 25 pence each ('Ordinary Shares')  
 ISIN: GB0009252882

- a) Description of the financial instrument

- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
- | c) Price(s) and volume(s) | Price(s) | Volume(s) |
|---------------------------|----------|-----------|
|                           | £14.516  | 141       |
|                           | £14.516  | 117       |
|                           | £14.516  | 167       |
|                           | £14.516  | 117       |

d) Aggregated information 543  
 Aggregated volume Price £14.516

e) Date of the transaction 2018-10-12

f) Place of the transaction London Stock Exchange  
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr S Dingemans

b) Position/status Chief Financial Officer

c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')  
 ISIN: GB0009252882

a) Description of the financial instrument

b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

| Price(s) | Volume(s) |
|----------|-----------|
| £14.516  | 274       |
| £14.516  | 205       |

c) Price(s) and volume(s)

£14.516 560

£14.516 274

£14.516 205

d) Aggregated information  
Aggregated volume Price

1518  
£14.516

e) Date of the transaction

2018-10-12

f) Place of the transaction

London Stock Exchange  
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr N Hirons

b) Position/status SVP, Global Ethics &  
Compliance

c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction  
platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type  
of instrument; (ii) each type of transaction; (iii) each date; and (iv)  
each place where transaction(s) has been conducted

Ordinary shares of 25 pence  
each ('Ordinary Shares')  
ISIN: GB0009252882

a) Description of the financial instrument

b) Nature of the transaction

Acquisition of Ordinary  
Shares following the  
re-investment of dividends  
paid to shareholders on 11

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

October 2018 on Ordinary  
Shares held in the Company's  
Deferred Annual Bonus Plan.

| Price(s) | Volume(s) |
|----------|-----------|
| £14.516  | 101       |

|         |    |
|---------|----|
| £14.516 | 74 |
|---------|----|

c) Price(s) and volume(s)

|         |    |
|---------|----|
| £14.516 | 88 |
|---------|----|

|         |     |
|---------|-----|
| £14.516 | 101 |
|---------|-----|

|         |    |
|---------|----|
| £14.516 | 74 |
|---------|----|

d) Aggregated information  
Aggregated volume Price

|     |         |
|-----|---------|
| 438 | £14.516 |
|-----|---------|

e) Date of the transaction

2018-10-12

f) Place of the transaction

London Stock Exchange  
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr B McNamara  
b) Position/status CEO, GSK Consumer Healthcare

c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction  
platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type  
of instrument; (ii) each type of transaction; (iii) each date; and (iv)  
each place where transaction(s) has been conducted

a) Description of the financial instrument American Depositary Shares  
(‘ADSs’)  
ISIN: US37733W1053

|                              |  |           |
|------------------------------|--|-----------|
|                              | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 October 2018 on ADSs held in the Company's Deferred Annual Bonus Plan. |           |
| b) Nature of the transaction | Price(s)   | Volume(s) |
|                              | \$38.47  | 84        |
| c) Price(s) and volume(s)    | \$38.47  | 82        |

|                           |         |
|---------------------------|---------|
| d) Aggregated information | 166     |
| Aggregated volume Price   | \$38.47 |

|                             |                                |
|-----------------------------|--------------------------------|
| e) Date of the transaction  | 2018-10-12                     |
| f) Place of the transaction | New York Stock Exchange (XNYS) |

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr L Miels
  - b) Position/status President, Global Pharmaceuticals
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

|  |  |
|--|--|
|  | Acquisition of Ordinary<br>Shares following the<br>re-investment of dividends<br>paid to shareholders on 11<br>October 2018 on Ordinary<br>Shares held in the Company's<br>Deferred Annual Bonus Plan. |
| b) Nature of the transaction                         |  |
| c) Price(s) and volume(s)                            | Price(s)      Volume(s)<br>£14.516      159  |
| d) Aggregated information<br>Aggregated volume Price | n/a (single transaction)   |
| e) Date of the transaction                           | 2018-10-12   |
| f) Place of the transaction                          | London Stock Exchange<br>(XLON)  |

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name      Mr D S Redfern
  - b) Position/status      Chief Strategy Officer
  - c) Initial notification/  
amendment      Initial notification
2. Details of the issuer, emission allowance market participant, auction  
platform, auctioneer or auction monitor
  - a) Name      GlaxoSmithKline plc
  - b) LEI      5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type  
of instrument; (ii) each type of transaction; (iii) each date; and (iv)  
each place where transaction(s) has been conducted
 

Ordinary shares of 25 pence  
each ('Ordinary Shares')  
ISIN: GB0009252882

a) Description of the financial instrument

|                              |   |
|------------------------------|---|
| b) Nature of the transaction | Acquisition of Ordinary<br>Shares following the<br>re-investment of dividends<br>paid to shareholders on 11 |
|------------------------------|---|



Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

October 2018 on Ordinary  
Shares held in the Company's  
Deferred Annual Bonus Plan.

| Price(s) | Volume(s) |
|----------|-----------|
| £14.516  | 129       |

|         |    |
|---------|----|
| £14.516 | 93 |
|---------|----|

|                           |         |     |
|---------------------------|---------|-----|
| c) Price(s) and volume(s) | £14.516 | 162 |
|---------------------------|---------|-----|

|         |    |
|---------|----|
| £14.516 | 93 |
|---------|----|

|         |     |
|---------|-----|
| £14.516 | 129 |
|---------|-----|

|                           |         |
|---------------------------|---------|
| d) Aggregated information | 606     |
| Aggregated volume         | £14.516 |

|                             |                                 |
|-----------------------------|---------------------------------|
| e) Date of the transaction  | 2018-10-12                      |
| f) Place of the transaction | London Stock Exchange<br>(XLON) |

1. Details of PDMR/person closely associated with them ('PCA')

|                    |                                       |
|--------------------|---------------------------------------|
| a) Name            | Ms K Terrell                          |
| b) Position/status | Chief Digital & Technology<br>Officer |

|                                       |                      |
|---------------------------------------|----------------------|
| c) Initial notification/<br>amendment | Initial notification |
|---------------------------------------|----------------------|

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

|         |                      |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc  |
| b) LEI  | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

|  |  |
|--|--|
| a) Description of the financial instrument | American Depositary Shares<br>(‘ADSs’)<br>ISIN: US37733W1053 |
|--|--|

|                              |  |          |           |         |    |
|------------------------------|--|----------|-----------|---------|----|
|                              | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 October 2018 on ADSs held in the Company's Deferred Annual Bonus Plan. |          |           |         |    |
| b) Nature of the transaction |  |          |           |         |    |
| c) Price(s) and volume(s)    | <table border="0"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>\$38.47</td> <td>28</td> </tr> </table>  | Price(s) | Volume(s) | \$38.47 | 28 |
| Price(s)                     | Volume(s)  |          |           |         |    |
| \$38.47                      | 28   |          |           |         |    |
| d) Aggregated information    | n/a (single transaction)   |          |           |         |    |
| e) Date of the transaction   | 2018-10-12   |          |           |         |    |
| f) Place of the transaction  | New York Stock Exchange (XNYS)   |          |           |         |    |

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms C Thomas
  - b) Position/status SVP, Human Resources
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 

Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

a) Description of the financial instrument

|                              |  |
|------------------------------|--|
| b) Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 |
|------------------------------|--|

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

October 2018 on Ordinary  
Shares held in the Company's  
Deferred Annual Bonus Plan.

| Price(s) | Volume(s) |
|----------|-----------|
| £14.516  | 189       |

|         |     |
|---------|-----|
| £14.516 | 141 |
|---------|-----|

|                           |         |     |
|---------------------------|---------|-----|
| c) Price(s) and volume(s) | £14.516 | 177 |
|---------------------------|---------|-----|

|         |     |
|---------|-----|
| £14.516 | 189 |
|---------|-----|

|         |     |
|---------|-----|
| £14.516 | 141 |
|---------|-----|

|                           |         |
|---------------------------|---------|
| d) Aggregated information | 837     |
| Aggregated volume Price   | £14.516 |

|                             |                                 |
|-----------------------------|---------------------------------|
| e) Date of the transaction  | 2018-10-12                      |
| f) Place of the transaction | London Stock Exchange<br>(XLON) |

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr P C Thomson
  - b) Position/status President, Global Affairs
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

|   |  |           |
|---|--|-----------|
| b) Nature of the transaction                        | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. |           |
|   | Price(s)   | Volume(s) |
|   | £14.516  | 115       |
| c) Price(s) and volume(s)                           | £14.516  | 88        |
|   | £14.516  | 110       |
| d) Aggregated information<br>Aggregated volumePrice | 313  | £14.516   |
| e) Date of the transaction                          | 2018-10-12   |           |
| f) Place of the transaction                         | London Stock Exchange<br>(XLON)  |           |

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: October 17, 2018

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc